General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Baudax Bio Announces Corporate Update | globenewswire.com • |
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag | zacks.com • |
Why Is Baudax Bio (BXRX) Stock Up 75% Today? | investorplace.com • |
Baudax Bio shares rocket as lead clinical candidate gains FDA orphan drug designation | proactiveinvestors.com • |
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors | globenewswire.com • |
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock Now | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-03-07 | 2023-12 | -0.12 | N/A | N/A | N/A |
2023-11-20 | 2023-09 | -0.53 | N/A | N/A | N/A |
2023-08-16 | 2023-06 | -2.04 | N/A | N/A | N/A |
2023-05-12 | 2023-03 | 5.75 | N/A | N/A | N/A |
2023-02-23 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -21.2 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-01-02 | Noble Capital Markets | Downgrade | Outperform | Market Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-06-14 | ASHTON WILLIAM L | Director | 42.53K | Stock Award(Grant) |
2022-06-14 | BASKIES ARNOLD M | Director | 41.94K | Stock Award(Grant) |
2022-06-14 | CHURCHILL WINSTON J. JR. | Director | 46.82K | Stock Award(Grant) |
2022-06-14 | DILMORE JILLIAN | Officer | 15.74K | Stock Award(Grant) |
2022-06-14 | DRECHSLER ANDREW T | Director | 41.66K | Stock Award(Grant) |
2022-12-14 | HENWOOD GERALDINE A | Chief Executive Officer | 2.44K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Creative Planning | 45.00K | 52.65K | 0.49% |
2023-06-29 | Jane Street Group, LLC | 27.34K | 31.99K | 0.30% |
2023-06-29 | Vanguard Group Inc | 24.90K | 29.13K | 0.27% |
2023-06-29 | State Street Corporation | 11.60K | 13.57K | 0.13% |
2023-06-29 | Tower Research Capital LLC (TRC) | 10.56K | 12.35K | 0.12% |
2023-06-29 | UBS Group AG | 9.66K | 11.30K | 0.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 24.90K | 29.13K | 0.27% |
2023-05-30 | Fidelity Extended Market Index Fund | 919.00 | 482.00 | 0.01% |
Split | Date |
---|---|
1 : 40 | 2022-12-01 |
1 : 35 | 2022-02-16 |
$BXRX I mean seriously how many times do we need to hit $3.68; $3.69 and $3.70? Everytime being stopped to fly upward??!!
$BXRX seriously should be above $5 already
$BXRX what is the deal with $3.70…..break it already…..
$BXRX This baby is going to SOAR before we know it. Super excited for what’s to come with this stock. I can’t believe more people don’t know about it! Do your DD & research ppl! Do genuine research and don’t listen to the paid bashers or articles. Great things to come. Very exciting!
$BXRX THIS WILL FLY!
Fellas, this will be 0.49c soon in a few days trading and my advice is let’s buy the DEEP big time and then seat back and relax.
Give it time fda approval doesn’t mean market approval. Let’s see if they can drive revenue
Get out while you can, burning machine cash with no revenue
Opinions are like fast food restaurants selling fake food, they are everywhere and have little to no value.
With the way this is going a reverse split of 10:1 is inevitable.
I just want it to be $4 soon
Didn’t sell before and not selling till $4.99
What a pos
Democrat buddy “if I’d known it would be this bad, I’d never had voted for Biden”.
Expensive lesson
We still liking Biden or nah?